













Global TB Report ←

This is the first time in many years an increase has been reported in the number of people falling ill with TB and drug resistant TB.

TB services are among many others disrupted by the COVID-19 pandemic in 2021, but its impact on the TB response has been particularly severe.

Many people with TB were not diagnosed and treated. The reported number of people newly diagnosed with TB fell from 7.1 million in 2019 to 5.8 million in 2020. There was a partial recovery to 6.4 million in 2021, but this was still well below pre-pandemic levels.

The number of people provided with treatment for RR-TB and multidrug-resistant TB (MDR-TB) has also declined between 2019 and 2020.

The report notes a decline in global spending on essential TB services from US\$6 billion in 2019 to US\$5.4 billion in 2021, which is less than half of the global target of US\$13 billion annually by 2022.

Concerns

TUBERCULOSIS

India has set a target to eliminate TB by 2025.Experts believe that to reach this goal, the country must go beyond the medical aspects.

Undernutrition is a major risk factor that drives TB, acknowledges the World Health Organization. The condition accounts for nearly 34 per cent of all cases.

Way forward •

The government needs to take stock of where the bottlenecks are. There is no point in pouring more money into a failing system

Drug-resistant tuberculosis remains a public health crisis, and ongoing surveillance of the burden is essential to mounting an effective response. Accurate diagnosis and treatment of tuberculosis, including drug-resistant forms, should be available and accessible to all who need it.

Closing gaps in the detection of drug-resistant tuberculosis requires investment in laboratory capacity, sample transport systems, and data connectivity solutions. To improve detection requires a multistep process, first requiring improved bacteriological confirmation among presumptive cases of pulmonary tuberculosis.

Efforts are needed to minimise the emergence of resistance to the first new drugs to be made available for the treatment of tuberculosis. Early detection of resistance relies on investment in research and development of new molecular tools.

About

Tuberculosis (TB) is a potentially serious infectious disease that mainly affects the lungs.

The 'Mycobacterium tuberculosis'bacteria that cause TB are spread when an infected person coughs or sneezes.

Most people infected with the bacteria that cause tuberculosis don't have symptoms. When symptoms do occur, they usually include a cough (sometimes blood-tinged), weight loss, night sweats and fever.

Treatment isn't always required for those without symptoms. Patients with active symptoms will require a long course of treatment involving multiple antibiotics.

As in the previous 10 years, most of the funding used in 2021 (79%) was from domestic sources. In other low- and middle-income countries, international donor funding remains crucial.

Present status in India

Tuberculosis is one of India's major public health problems. According to World Health Organisation (WHO) estimates, India has the world's largest tuberculosis epidemic.

In 2020, India accounted for 26% of the incident TB cases across the globe.

India has an incidence rate of 192 cases per 100,000 of population.

India accounted for 38% of global TB deaths among HIV-negative people and for 34% of the combined total number of TB deaths in HIV-negative and HIV-positive people. Further in 2020, India accounted for 24% of the global gap between estimated TB incidence and the number of people newly diagnosed with TB and reported.

Global targets

In 2014 and 2015, all Member States of WHO and the UN adopted the UN Sustainable Development Goals (SDGs) and WHO's End TB Strategy. The SDGs and End TB Strategy both include targets and milestones for large reductions in TB incidence, TB deaths and costs faced by TB patients and their households.

In 2018, countries convened at the United Nations (UN) highlevel meeting on TB committed to speed up work towards ambitious targets to treat an additional 40 million people with TB and provide preventive treatment to at least 30 million people at risk of developing the disease by 2022.